‘Look before you leap’: Caribou to start Ph1 autoimmune study of CAR-T therapy

05 Apr 2024
endpts.com
Cell TherapyImmunotherapyINDClinical Study
Just like other cell therapy companies, Caribou Biosciences is entering the autoimmune disease field.
The Berkeley, CA-based biotech disclosed Thursday afternoon that the FDA cleared it to begin a clinical trial of its off-the-shelf cell therapy in lupus, and Caribou expects to start the Phase 1 study by the end of 2024.
Caribou is joining the herd of companies studying cell therapy for autoimmune conditions, where interest has exploded after an academic research group led by Georg Schett from the Friedrich-Alexander University Erlangen-Nürnberg reported striking results in a small group of patients with lupus and other autoimmune disorders. Other companies that have entered into the autoimmune cell therapy field recently include Nkarta and CRISPR Therapeutics.
‘Look before you leap’: Caribou to start Ph1 autoimmune study of CAR-T therapy
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.